ホーム › 卵巣がん › テキサス › San Antonio
San Antonio、TXにおける卵巣がんの臨床試験
San Antonioとその周辺地域（約30マイル以内）の拠点で、卵巣がんに関する31件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
被験者募集中第1/2相
- Research Site, San Antonio
A Study of PHST001 in Advanced Solid Tumors
被験者募集中第1相
- START Center for Cancer Research - San Antonio, San Antonio
- University of Texas (UT) Health, San Antonio
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
被験者募集中第1相
- South Texas Accelerated Research Therapeutics (START), San Antonio
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
被験者募集中第1相
- NEXT Oncology - San Antonio /ID# 278606, San Antonio
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
被験者募集中第1/2相
- NEXT Oncology, San Antonio
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
被験者募集中第1相
- NEXT Oncology - PARENT, San Antonio
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
被験者募集中第2相
- Texas Oncology - San Antonio Medical Center - Research Drive /ID# 275090, San Antonio
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
被験者募集中第2相
- Texas Oncology - San Antonio Medical Center - Research Drive /ID# 277735, San Antonio
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- NEXT Oncology San Antonio, San Antonio
- START Texas, San Antonio
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
被験者募集中第1/2相
- START Center for Cancer Research, San Antonio
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
被験者募集中第2相
- Texas Oncology-San Antonio Medical Center Pharmacy, San Antonio
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
被験者募集中観察研究
- The University of Texas Health Science Center at San Antonio, San Antonio
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
被験者募集中第1相
- START - San Antonio, San Antonio
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
被験者募集中第3相
- University Of Texas Health Science Center -San Antonio ( Site 0095), San Antonio
- Texas Oncology - San Antonio ( Site 8005), San Antonio
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
被験者募集中第1相
- START San Antonio, San Antonio
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
被験者募集中第1相
- UT Health San Antonio - MD Anderson Cancer Center, San Antonio
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
被験者募集中第1相
- Normunity Investigational Site, San Antonio
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- START San Antonio, San Antonio
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Clinical Trial Site, San Antonio
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
被験者募集中第1相
- START - San Antonio, San Antonio
IDOV-Immune for Advanced Solid Tumors
被験者募集中第1相
- South Texas Accelerated Research Therapeutics, San Antonio
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Texas Oncology - San Antonio, San Antonio
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
被験者募集中第1相
- NEXT San Antonio, San Antonio
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- START San Antonio, San Antonio
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- START, San Antonio
Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
被験者募集中健康なボランティア歓迎
- UT Health Science Center San Antonio, San Antonio
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- NEXT Oncology San Antonio, San Antonio
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
被験者募集中第1相
- START San Antonio, San Antonio
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
被験者募集中第1相
- Dren Investigational Site, San Antonio
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #3, San Antonio
他の都市における卵巣がんの試験
- Houston, TX89件の研究
- New York City, NY69件の研究
- Boston, MA61件の研究
- Los Angeles, CA50件の研究
- Nashville, TN49件の研究
- Arlington, VA46件の研究
- Philadelphia, PA44件の研究
- Columbus, OH39件の研究
- St. Louis, MO38件の研究
- Chicago, IL36件の研究
- Cleveland, OH30件の研究
- Pittsburgh, PA30件の研究
San Antonioにおける他の研究
- 非小細胞肺癌59件の研究
- 乳がん47件の研究
- 大腸癌46件の研究
- 転移性癌44件の研究
- がん（全種類）41件の研究
- 肥満症40件の研究
- 2型糖尿病37件の研究
- 過体重34件の研究
- 膵臓がん31件の研究
- 前立腺がん28件の研究
- 子宮内膜がん27件の研究
- 肺がん26件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。